NEW YORK, Oct. 6, 2015 /PRNewswire/ -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) shares closed at $6.15 yesterday, up .33%. Trading volume was higher than average at 5 million shares. The share price was $3.66 on September 30th and made the 68% jump on news of a new product release.
Our due diligence will show investors in Pacific Biosciences of California, Inc. the information they need about new technological developments, to make investment choices. Get our brief report at the link below.
http://bit.ly/-PACB_Due_Diligence_Report
Copy and paste to browser may be required.
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company provides single molecule real-time (SMRT) technology platform, which enables single molecule real-time detection of biological processes. It offers PacBio RS II high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source. A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-update-brokerbank-securities-provides-due-diligence-report-300155029.html
SOURCE BrokerBank Securities, Inc.
